Leukotrienes, leukotriene receptor antagonists, and rhinitis

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 55, Issue 5, 2000, Pages 421-424

  Mygind, N ^a   Dahl, R ^a   Bisgaard, H ^b   Mygind, Niels ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b Rigshospitalet   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; AZELASTINE; BECLOMETASONE DIPROPIONATE; LEUKOTRIENE; LEUKOTRIENE D4; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LIPOXYGENASE INHIBITOR; LORATADINE; MIZOLASTINE; MONTELUKAST; OVALBUMIN; PEPTIDOLEUKOTRIENE; PRANLUKAST; ZAFIRLUKAST; ZILEUTON;

AIRWAY RESISTANCE; DRUG EFFECT; EXPERIMENTAL ANIMAL; EXTRAVASATION; HUMAN; MUCUS SECRETION; NONHUMAN; NOSE POLYP; PRIORITY JOURNAL; PROVOCATION TEST; REVIEW; RHINITIS; RHINORRHEA; SENSORY NERVE; SMELLING; SNEEZING;

ANIMALS; ANTI-ASTHMATIC AGENTS; CLINICAL TRIALS; DRUG THERAPY, COMBINATION; HISTAMINE H1 ANTAGONISTS; HUMANS; LEUKOTRIENE ANTAGONISTS; LEUKOTRIENES; RHINITIS;

EID: 0034013717     PISSN: 01054538     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1398-9995.2000.00113.x     Document Type: Review

References (39)

1. 1. PAUWELS RA, Joos GF, KIPS JC. Leukotrienes as therapeutic targets in asthma. Allergy 1995;50:615-622.
2. 2. BUSSE WW. The role of leukotrienes in asthma and allergic rhinitis. Allergy 1996;26:868-879.
3. 3. HOLGATE ST, BRADDING P, SAMPSON AP. Leukotriene antagonists and synthesis inhibitors: new directions in asthma therapy. J Allergy Clin Immunol 1996;98:1-13.
4. 4. SPECTOR S. Management of asthma with zafirlukast. Drugs 1996;52 Suppl 6:36-46.
5. 5. LANE SJ. Leukotriene antagonists in asthma and rhinitis. Respir Med 1998;92:795-809.
6. 6. LIPWORTH BJ. Leukotriene-receptor antagonists. Lancet 1999;353:57-62.
7. 7. CALHOUN WJ, LAVINS B, MINKWITZ MC, EVANS R, GLEICH G, COHN J. Effect of zafirlukast (Accolate) on cellular mediators of inflammation: bronchoalveolar lavage fluid after segmental antigen challenge. J Respir Crit Care Med 1998;157:138-139.
8. 8. BISGAARD H, LOLAND L, ANHØJ J. NO in exhaled air of asthmatic children is reduced by the leukotriene receptor antagonist montelukast. Am J Respir Crit Care Med 1999 (in press).
9. 9. SHIRASAKI H, ASAKURA K, NARITA S-I, KALAURA A. The effect of a cysteinyl leukotriene antagonist, ONO-1078 (pranlukast), on agonist- and antigen-induced nasal microvascular leakage in guinea pigs. Rhinology 1998;36:62-65.
10. 10. FUJITA M, YONFTOMI Y, SHIMOUCHI K, et al. Involvement of cysteinyl leukotrienes in biphasic increase of nasal airway resistance of antigen-induced rhinitis in guinea pigs. Eur J Pharmacol 1999;369:349-356.
11. 11. LIU YC, KHAWAJA AM, ROGERS DF. Effects of the cysteinyl leukotriene receptor antagonists pranlukast and zafirlukast on tracheal mucus secretions in ovalbumin-sensitized guinea-pigs in vitro. Br J Pharmacol 1998;124:563-571.
12. 12. CRETICOS PS, PETERS SP, ADKINSON NF, et al. Peptide leukotriene release after antigen challenge in patients with sensitivity to ragweed. N Engl J Med 1984;310:1626-1630.
13. 4 in grass pollen-induced rhinitis. Am Rev Respir Dis 1987;136:357-362.
14. 4 as a mediator of early and late reactions to antigen in humans: the effect of systemic glucocorticoid treatment in vivo. J Allergy Clin Immunol 1989;83:634-642.
15. 15. GEORGITIS JW, SIONE BD, GOTTSCHLICH G. Nasal inflammatory mediator release in ragweed allergic rhinitis correlation with cellular influx into nasal secretions. Int Arch Allergy Appl Immunol 1991;96:231-237.
16. 16. NACLERIO RM, BAROODY FM, TOGIAS AG. The role of leukotrienes in allergic rhinitis a review. Am Rev Respir Dis 1991;143(Suppl):S91-S95.
17. 17. WANG D, CLEMENT P, SMITZ J, DERDE MP. Concentrations of chemical mediators in nasal secretions after nasal allergen challenges in atopic patients. Eur Arch ORL 1995;252 Suppl 1:S40-S43.
18. 4 release in upper respiratory mucosa during natural exposure to ragweed in ragweed-sensitive children. J Allergy Clin Immunol 1988;82:414.
19. 19. SKONER DP, LEE L, DOYLE WJ. Nasal physiology and inflammatory mediators during natural pollen exposure. Ann Allergy 1990;65:206-210.
20. 20. WANG D, CLEMENT P, SMITZ J, DERDE M-P. Concentrations of chemical mediators in nasal secretions of patients with hay fever during allergen exposure. Acta Otolaryngol (Stockh) 1994;114:552-555.
21. 4 on nasal mucosal blood flow, nasal airway resistance and nasal secretions in humans. Clin Allergy 1986;16:289-297.
22. 4 in allergic rhinitis. Ann Allergy 1988;60:537-540.
23. 23. GRONBORG H, BORUM P, MYGIND N. Histamine and methacholine do not induce nasal reactivity. Clin Allergy 1986;16:597-602.
24. 24. LUNDGREN JD, SHELHAMMER JH. Pathogenesis of airway mucus hypersecretion. J Allergy Clin Immunol 1990;85:399-417.
25. 4 and histamine in exogenous asthma. BMJ 1985;290:1468-1471.
26. 26. BISGAARD H, GROTH S. Bronchial effects of LTD4 inhalation in normal human lung. Clin Sci 1987;72:585-592.
27. 4 and to methacholine in patients with asthma and normal controls. N Engl J Med 1996;315:480-484.
28. 4-receptor antagonist ICI 204,219 relieves symptoms of acute seasonal allergic rhinitis. Am J Respir Crit Care Med 1995;151:1734-1739.
29. 29. MALMSTRÖM K, MELTZER EO, BRENNER BP, et al. Concomitant montelukast and loratadine provide rapid significant improvement in seasonal allergic rhinitis compared with loratadine alone. 1999 (in press).
30. 30. NUMATA T, KONNO A, YAMAKOSHI T, HANAZAWA T, TERADA N, NAGATA H. Comparative role of peptide leukotrienes and histamine in the development of nasal mucosal swelling in nasal allergy. Ann Otol Rhinol Laryngol 1999;108:467-473.
31. 31. PULLERITS T, PRASKS L, SKOOGH B-E, ANI R, LÖTVALL J. Randomized placebo-controlled study comparing a leukotriene receptor antagonist and a nasal glucocorticoid in seasonal allergic rhinitis. Am J Respir Crit Care Med 1999;159:1814-1818.
32. 32. HOWARTH PH, HARRISON K, LAU L. The influence of 5-lipoxygenase inhibition in allergic rhinitis. Int Arch Allergy Immunol 1995;107:423-424.
33. 33. KNAPP HR. Reduced allergen-induced nasal congestion and leukotriene synthesis with an orally active 5-lipoxygenase inhibitor. N Engl J Med 1990;323:1745-1748.
34. 34. ISRAEL E, FISHER AR, ROSENBERG MA, et al. The pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin. Am Rev Respir Dis 1993;148:1447-1451.
35. 35. FISHER AR, ROSENBERG MA, LILLY CM, et al. Direct evidence for the role of the mast cell in nasal response to aspirin in aspirin-sensitive asthmatics. J Allergy Clin Immunol 1994;94:1046-1056.
36. 36. DAHLÉN B, NIZANKOWSKA E, SZCZEKLIK A, et al. Benefit from adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin-intolerant asthmatics. Am J Respir Crit Care Med 1998;157:1187-1194.
37. 37. BACHERT C, LANGE B. Histamine und Leukotriene bei der allergischen Rhinitis. Allergologie 1999;22:492-507.
38. 38. GASPAR H, NOLTE D, AURICH R. Comparative efficacy of azelastine nasal spray and terfenadine in seasonal and perennial rhinilis. Allergy 1994;49:152-158.
39. 39. BELLIONE P. Comparison of mizolastine and loratadine in the treatment of perennial allergic rhinitis. Rhinology 1996;34:101-104.